GILD logo

GILD Gilead Sciences, Inc.

NASDAQ Global Select · Drug Manufacturers - General · Healthcare

$168.98
-1.28 (-0.75%)

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it su…

Market Cap: $209.59Bwww.gilead.com

Price

No data yet.

Social Signal Score

55
5d
50
3 mentions
—
30d
56
40 mentions
—
60d
57
58 mentions
—
90d
55
85 mentions
—
news: 60 · rss: 19 · marketaux: 4 · 4chan: 1 · podcast: 1

Analyst Ratings

58 analysts
Buyconsensus
Strong Buy 0Buy 39Hold 18Sell 1Strong Sell 0
Avg price target$167.94-0.6%
Low $126Median $173.5High $196
Current Consensus

Revenue

$8.30B+13.39%
$5.09B$6.16B$7.23B$8.30B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$8.11
$7.99–$8.22
19 analysts
FY2026
$-0.95-112% YoY
$-1.31–$-0.34
16 analysts
FY2027
$10.15
$9.46–$12.46
16 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Daniel O'Day
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
17,000
Beta
0.36
Country
US
Piotroski score
5 / 9 (Middling)
Altman Z-score
3.99
www.gilead.com